

January 2, 2019



CymaBay Therapeutics to Present at the 37th Annual J.P. Morgan Healthcare Conference

NEWARK, Calif., Jan. 02, 2019 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced that Sujal Shah, President and Chief Executive Officer, will provide a corporate overview at the 37th Annual J.P. Morgan Healthcare Conference in San Francisco, CA on Wednesday, January 9, 2019 at 4:30pm PT.

A live audio webcast of the presentation can be accessed through the Investors section of the CymaBay Therapeutics corporate website at <http://ir.cymabay.com/events>. The webcast will be archived on the corporate website for 90 days.

About CymaBay

CymaBay Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet medical need. Seladelpar is a potent, selective, orally active PPAR δ agonist, currently in development for the treatment of patients with primary biliary cholangitis (PBC), an autoimmune liver disease, and with nonalcoholic steatohepatitis (NASH). Two Phase 2 studies of seladelpar established proof-of-concept in PBC. CymaBay is currently enrolling patients in a global, Phase 3 registration study of seladelpar for PBC. This study is a 52-week, placebo-controlled, randomized, Phase 3 study to evaluate the safety and efficacy of seladelpar (ENHANCE) in patients with PBC. CymaBay is also conducting a Phase 2b proof-of-concept study of seladelpar for patients with NASH.

For additional information about CymaBay visit www.cymabay.com.

Contact:

Hans Vitzthum
LifeSci Advisors, LLC
212-915-2568

Hans@LifeSciAdvisors.com



Source: CymaBay Therapeutics, Inc.

